CE20 - Biologie des animaux, des organismes photosynthétiques et des microorganismes

CelBoVax: Novel comprehensive approach to shape cattle cell-mediated immunity – CelBoVax

Novel comprehensive approach to shape cattle cell-mediated immunity

Limiting the overall use of antibiotics constitutes a topical challenge for food animal industry. To reach this objective, vaccination plays a critical role by reducing the incidence and severity of high-impact diseases. At present, new alternatives to conventional antibody-based vaccines are necessary for controlling numerous animal diseases. In this context, CelBoVax proposes an innovative approach to produce next-generation vaccines aimed at boosting cattle cell-mediated immunity.

CelBoVax is aimed at setting up a novel approach to produce next-generation vaccines able to shape bovine cellular immunity.

CelBoVax is aimed at setting up a novel approach to produce next-generation vaccines able to shape bovine cellular immunity. <br /><br />As proof-of-concept, we will target Staphylococcus aureus, a major pathogen of dairy cows. By combining multidisciplinary approaches, our efforts will be focused on each step of a prototype vaccine production pipeline including: development and selection of new yeast-based antigen delivery systems, identification of pertinent candidate antigens by state-of-the-art proteomics and in silico analysis and setting up of simple and affordable assays to test the in vivo activity of candidate vaccines.<br /><br />The innovative aspects of our strategy are i) use of inactivated yeasts as safe, inexpensive and easy-to-store adjuvant-free vaccine platforms; ii) selection of antigen delivery vectors able to induce cellular immunity in bovine; iii) integration of in cellulo and in silico methods for a targeted screening of candidate antigens based on their relevance as T-cell response inducers; iv) development of novel strategies to evaluate the in vivo activity of candidate vaccines for cattle, circumventing experimental infections.

The yeast surface display (YSD) technology was employed to produce novel antigen delivery systems.

Bacterial peptides associated with BoLA-I and BoLA-II (presented in the context of MHC-I and MHC-II, respectively) will be identified by immunopeptidomics analysis.

Two vaccine formulations targeting stahpylococcal mastitis will be tested in vivo using an approach circumventing infectious challenges.

A Saccharomyces cerevisiae prototype vaccine could stimulate bovine memory T-cells in vivo.

A yeast-based prototype vaccine proved to be safe for in vivo usage in bovine.

These preliminary results provided a solid proof of concept that will enable us to improve our vaccine formulation and our immunisation protocols.

Yeast-based antigen vectors
Yeast-based antigen vaccines for bovine
Staphylococcus candidate antigen for vaccine development.

Limiting the overall use of antibiotics constitutes a topical challenge for food animal industry. To reach this objective, vaccination plays a critical role by reducing the incidence and severity of high-impact diseases. At present, new alternatives to conventional antibody-based vaccines are necessary for controlling numerous animal diseases. In this context, CelBoVax proposes an innovative approach to produce next-generation vaccines aimed at boosting cattle cell-mediated immunity. As proof-of-concept, we will target Staphylococcus aureus, a major pathogen of dairy cows. By combining multidisciplinary approaches, our efforts will be focused on each step of a prototype vaccine production pipeline including: development and selection of new yeast-based antigen delivery systems, identification of pertinent candidate antigens by state-of-the-art proteomics and in silico analysis and setting up of simple and affordable assays to test the in vivo activity of candidate vaccines.

Project coordination

Rodrigo Prado Martins (Infectiologie et Santé Publique)

The author of this summary is the project coordinator, who is responsible for the content of this summary. The ANR declines any responsibility as for its contents.

Partner

INRAE - ISP Infectiologie et Santé Publique

Help of the ANR 339,999 euros
Beginning and duration of the scientific project: March 2021 - 42 Months

Useful links

Explorez notre base de projets financés

 

 

ANR makes available its datasets on funded projects, click here to find more.

Sign up for the latest news:
Subscribe to our newsletter